Arbor Biotechnologies™ - Home
Arbor Biotechnologies is a next-generation gene editing company based in Cambridge, MA, advancing a pipeline of novel genomic medicines for patients with genetic diseases. The company discovers and develops programmable DNA editors — building on CRISPR with advanced proprietary tools — to enable curative outcomes across liver, CNS, and other disease areas. Arbor partners with global pharmaceutical leaders to bring its editing platform to clinical-stage programs.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2025
Nov 2021
Jun 2017
Create a free account to see which investors have funded this company.
Create Free Account
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
